BioTuesdays

Tag - Cantor Fitzgerald

SELLAS Life Sciences Logo

Cantor starts SELLAS Life Sciences at OW; PT $18

Cantor Fitzgerald launched coverage of SELLAS Life Sciences (NASDAQ:SLS) with an “outperform” rating and $18 price target. The stock closed at $8.60 on July 20. SELLAS is a late-stage immune-oncology company that is...

Novan logo

Cantor starts Novan at OW; PT $30

Cantor Fitzgerald initiated coverage of Novan (NASDAQ:NOVN) with an “overweight” rating and $30 price target. The stock closed at $9.10 on July 8. Novan is a clinical-stage biotechnology company focused on leveraging...

Jaguar Health Logo

Cantor starts Jaguar Health at OW; PT $5

Cantor Fitzgerald initiated coverage of Jaguar Health (NASDAQ:JAGX) with an “overweight” rating and price target of $5. The stock closed at $1.49 on July 6. Jaguar Health is a commercial-stage pharmaceuticals company...

Arcturus Logo

Cantor starts Arcturus Therapeutics at OW; PT $71

Cantor Fitzgerald launched coverage of Arcturus Therapeutics (NASDAQ:ARCT) with an “overweight” rating and $71 price target. The stock closed at $35.94 on July 1. Arcturus is leveraging its proprietary lipid-based...

Sanara MedTech Logo

Cantor starts Sanara MedTech at OW; PT $45

Cantor Fitzgerald launched coverage of Sanara MedTech (NASDAQ:SMTI) with an “overweight” rating and a 12-month price target of $45. The stock closed at $36.66 on June 29. Sanara has built a portfolio of differentiated...

Lipocine

Cantor starts Lipocine at OW; PT $3

Cantor Fitzgerald initiated coverage of Lipocine (NASDAQ:LPCN) with an “overweight” rating and 12-month price target of $3. The stock closed at $1.36 on June 23. “We think Lipocine has multiple shots on goal across its...

Cantor starts Evelo Biosciences at OW; PT $28

Cantor Fitzgerald launched coverage of Evelo Biosciences (NASDAQ:EVLO) with an “overweight” rating and 12-month price target of $28. The stock closed at $16.08 on June 22. Evelo is developing oral therapies derived from...

RAPT-Therapeutics

Cantor ups RAPT Therapeutics PT to $71 from $51

Cantor Fitzgerald raised its price target for RAPT Therapeutics (NASDAQ:RAPT) to $71 from $51, citing an increased probability of success for RPT193 in atopic dermatitis to 50% from 25% previously, and taking up peak...

CareCloud

Cantor starts CareCloud at OW: PT $15

Cantor Fitzgerald launched coverage of CareCloud (NASDAQ:MTBC) with an “overweight” rating and $15 price target. The stock closed at $8.54 on June 10. CareCloud, formerly known as MTBC Inc., provides a broad range of...

Cutera

Cantor starts Cutera at OW; PT $55

Cantor Fitzgerald initiated coverage of Cutera (NASDAQ:CUTR) with an “overweight” rating and 12-month price target of $55. The stock closed at $40.86 on June 1. “Cutera’s comprehensive portfolio of innovative aesthetic...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.